Literature DB >> 22341538

The use of antiviral drugs during the neonatal period.

Richard J Whitley1.   

Abstract

Parenteral therapy of viral infections of the newborn and infant began with vidarabine (adenine arabinoside) for the treatment of neonatal herpes simplex virus (HSV) infections in the early 1980s. Acyclovir has become the treatment of choice for neonatal HSV infections and a variety of other herpesvirus infections. Ganciclovir is beneficial for the treatment of congenital cytomegalovirus (CMV) infections involving the central nervous system (CNS). This article reviews the use of acyclovir and ganciclovir in the treatment of neonatal HSV and congenital CMV infections. A brief summary precedes a detailed discussion of available established and alternative therapeutics.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341538      PMCID: PMC3290126          DOI: 10.1016/j.clp.2011.12.004

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  54 in total

1.  Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease.

Authors:  G J Demmler
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

2.  Cytomegalovirus infection of extremely low-birth weight infants via breast milk.

Authors:  J Maschmann; K Hamprecht; K Dietz; G Jahn; C P Speer
Journal:  Clin Infect Dis       Date:  2001-11-12       Impact factor: 9.079

3.  Clinical uses of cidofovir.

Authors: 
Journal:  Rev Med Virol       Date:  1997-09       Impact factor: 6.989

4.  Effect of renal failure on the pharmacokinetics of acyclovir.

Authors:  O L Laskin; J A Longstreth; A Whelton; H C Krasny; R E Keeney; L Rocco; P S Lietman
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

5.  Natural history of neonatal herpes simplex virus infections in the acyclovir era.

Authors:  D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L M Frenkel; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S J Soong; J Kiell; F D Lakeman; R J Whitley
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

6.  (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.

Authors:  J P Lalezari; W L Drew; E Glutzer; C James; D Miner; J Flaherty; P E Fisher; K Cundy; J Hannigan; J C Martin
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

7.  Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis.

Authors:  S K Swan; M Y Munar; M A Wigger; W M Bennett
Journal:  Am J Kidney Dis       Date:  1991-01       Impact factor: 8.860

8.  Acyclovir resistant varicella zoster and HIV infection.

Authors:  E G Lyall; M M Ogilvie; N M Smith; S Burns
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

Review 9.  Management of HSV encephalitis in adults and neonates: diagnosis, prognosis and treatment.

Authors:  David W Kimberlin
Journal:  Herpes       Date:  2007-06

Review 10.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

View more
  10 in total

1.  Impact of a Rapid Herpes Simplex Virus PCR Assay on Duration of Acyclovir Therapy.

Authors:  Tam T Van; Kanokporn Mongkolrattanothai; Melissa Arevalo; Maryann Lustestica; Jennifer Dien Bard
Journal:  J Clin Microbiol       Date:  2017-03-08       Impact factor: 5.948

2.  TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate.

Authors:  Gloria Komazin-Meredith; Steven C Cardinale; Katelyn Comeau; Kevin J Magalhaes; Caroll B Hartline; John D Williams; Timothy J Opperman; Mark N Prichard; Terry L Bowlin
Journal:  Antiviral Res       Date:  2015-04-07       Impact factor: 5.970

3.  Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes.

Authors:  Quanhathai Kaewpoowat; Lucrecia Salazar; Elizabeth Aguilera; Susan H Wootton; Rodrigo Hasbun
Journal:  Infection       Date:  2015-12-17       Impact factor: 3.553

Review 4.  Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update.

Authors:  John Brock Harris; Amy P Holmes
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Mar-Apr

5.  HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships.

Authors:  Elaine L Bearer
Journal:  Future Virol       Date:  2012-09       Impact factor: 1.831

Review 6.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

7.  Bilateral cytomegalovirus retinitis in a healthy infant.

Authors:  Seyedeh Maryam Hosseini; Mir-Naghi Moosavi; Naser Shoeibi; Mehdi Sakhaee; Hossein Ghavamsaeedi
Journal:  J Curr Ophthalmol       Date:  2016-12-23

8.  Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.

Authors:  Seth M Schneider; Suzanne M Pritchard; George A Wudiri; Chasity E Trammell; Anthony V Nicola
Journal:  mBio       Date:  2019-05-14       Impact factor: 7.867

9.  Economic Evaluation: Onsite HSV PCR Capabilities for Pediatric Care.

Authors:  Zachary Weber; Deena Sutter; Austin Baltensperger; Nicholas Carr
Journal:  Pediatr Qual Saf       Date:  2020-03-10

10.  Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.

Authors:  Morna J Dorsey; Nicola A M Wright; Natalia S Chaimowitz; Blachy J Dávila Saldaña; Holly Miller; Michael D Keller; Monica S Thakar; Ami J Shah; Rolla Abu-Arja; Jeffrey Andolina; Victor Aquino; J L Barnum; Jeffrey J Bednarski; Monica Bhatia; Francisco A Bonilla; Manish J Butte; Nancy J Bunin; Sharat Chandra; Sonali Chaudhury; Karin Chen; Hey Chong; Geoffrey D E Cuvelier; Jignesh Dalal; Magee L DeFelice; Kenneth B DeSantes; Lisa R Forbes; Alfred Gillio; Fred Goldman; Avni Y Joshi; Neena Kapoor; Alan P Knutsen; Lisa Kobrynski; Jay A Lieberman; Jennifer W Leiding; Benjamin Oshrine; Kiran P Patel; Susan Prockop; Troy C Quigg; Ralph Quinones; Kirk R Schultz; Christine Seroogy; David Shyr; Subhadra Siegel; Angela R Smith; Troy R Torgerson; Mark T Vander Lugt; Lolie C Yu; Morton J Cowan; Rebecca H Buckley; Christopher C Dvorak; Linda M Griffith; Elie Haddad; Donald B Kohn; Brent Logan; Luigi D Notarangelo; Sung-Yun Pai; Jennifer Puck; Michael A Pulsipher; Jennifer Heimall
Journal:  J Clin Immunol       Date:  2020-10-02       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.